The Rx-to-OTC switch of Claritin, Allegra, and Zyrtec: an unprecedented FDA response to petitioners and the protection of public health.
Holly M
HM
Spencer
D018926:Anti-Allergic Agents; D017332:Cetirizine; D017277:Drug Approval; D016527:Drug Costs; D004348:Drug Labeling; D011307:Drug Prescriptions / Q000191:economics; D020793:Gatekeeping / Q000331:legislation & jurisprudence; D006801:Humans; D007880:Legislation, Drug; D017336:Loratadine; D004366:Nonprescription Drugs / Q000191:economics; D015980:Public Health Practice; D016593:Terfenadine / Q000031:analogs & derivatives; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence
D018926:Anti-Allergic Agents; D004366:Nonprescription Drugs; D017336:Loratadine; D016593:Terfenadine; D017332:Cetirizine